Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + BCG
- Development stage
- Phase 4
- Lead developer
- BeiGene
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intravesical
01
Overview
Tislelizumab + BCG is a combination therapy under investigation for high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Tislelizumab is a humanized IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1 and PD-L2, thereby restoring T-cell function and enhancing immune-mediated antitumor responses. Bacillus Calmette–Guérin (BCG) is an intravesical immunotherapy using live attenuated Mycobacterium bovis to stimulate local immune responses in the bladder. The combination aims to leverage both systemic checkpoint inhibition and local immune activation for improved efficacy in HR-NMIBC, particularly in patients unresponsive to or relapsing after standard BCG therapy[2][4][7].
- Brand names
- Tevimbra
- Other names
- bacillus Calmette-Guérinbacillus-calmette guérinBCG
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on tislelizumab + BCG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + BCG.